APAC IPOs & Placements, Aequitas Research

Clarence Chu

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Shiva Pharmachem Limited / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shiva-pharmachem-limited" target="_blank" data-smartkarma-citation="entities:40109:1" rel="noopener">Shiva Pharmachem Limited (9155347Z IN)</a> is looking to raise around US$110m in its upcoming India IPO. The bookrunners on the deal are JM Financial and Kotak.</li>
<li>Shiva PharmaChem (SP) is a manufacturer in the Indian specialty chemicals business. </li>
<li>As per Frost &amp; Sullivan (F&amp;S), the firm is the largest manufacturer of acid and alkyl chlorides by volume in CY22 in India and a key player globally.</li>
</ul>



Shiva Pharmachem Limited (9155347Z IN) is looking to raise around US$110m in its upcoming India IPO. The bookrunners on the deal are JM Financial and Kotak.
Shiva PharmaChem (SP) is a manufacturer in the Indian specialty chemicals business. 
As per Frost &amp; Sullivan (F&amp;S), the firm is the largest manufacturer of acid and alkyl chlorides by volume in CY22 in India and a key player globally.


Shiva Pharmachem Limited

Shiva Pharmachem Pre-IPO Tearsheet